Search Results 251-260 of 10429 for Terminal

  1. https://www.mayoclinic.org/condition_consolidated_concepts.xml

  2. A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment - Mayo Clinic

    > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum; fulminant colitis;; toxic ...

  3. https://www.mayoclinic.org/arabic_condition_consolidated_concepts.xml

  4. https://www.mayoclinic.org/arabic_patient_consumer_faq.xml

  5. Gastroenterology and Hepatology - Clinical trials

    [MUSIC PLAYING]. Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first.

  6. Publications - Membrane Trafficking in Disease - Mayo Clinic Research

    Pitts KR, McNiven MA, Yoon Y. Mitochondria-specific function of the dynamin family protein DLP1 is mediated by its C-terminal domains. Journal of Biochemistry.

  7. Cardiovascular Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Patients - Mayo Clinic

    ... Terminal pro- brain natriuretic peptide NT-proBNP ≥1500 pg/ml measured within 90 days prior to subject registration ("corrected" refers to a 4% reduction ...

  8. Ultrasound Evaluation of Crohn's Disease - Mayo Clinic

    Crohn's disease patients with involvement of terminal ileum (thickness > 3mm) or other segments of small or large bowel; Aage above 18. Exclusion Criteria ...

  9. Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study (CHESS) - Mayo Clinic

    Life expectancy of less than 6 months due to comorbid terminal conditions. 20. Concurrent participation in another research protocol for investigation of an ...

  10. A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of NIO752 In Participants With Progressive Supranuclear Palsy - Mayo Clinic

    Sexually active males, unless they always use condoms during intercourse while taking study drug and for 15 weeks (= 5 times the expected plasma terminal half- ...